Released Aug 2, 2017, after the close
10-Q filed Aug 4, 2017, 35 days after period end · 0001493152-17-008543
Q2 2017 · 10-Q
Revenue$5.55M$5.55M +2.6% vs Q2 2016+6.1% vs Q1 2017
Net Income-$164.00K-$164.00K N/M vs Q2 2016N/M vs Q1 2017
EPS Diluted-$0.07-$0.07 N/M vs Q2 2016N/M vs Q1 2017
Operating Income-$26,000N/M
Operating Cash Flowderived$3,272,000+532.9%
Free Cash Flowderived$3,030,000+651.9%
Margins · derived
Operating margin-0.5%+12.4 pt vs Q2 2016
Net margin-3.0%+12.8 pt vs Q2 2016
What the release said
The release
Same quarter
| Metric | Q2 2017 | Q2 2016 | Q2 2015 | Q2 2014 |
|---|---|---|---|---|
| Revenue | $5.55M | $5.41M | $6.19M | $6.87M |
| Net Income | -$164.00K | -$850.00K | -$2.63M | -$1.35M |
| EPS Diluted | -$0.07 | -$0.46 | -$1.43 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR